3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Brain Neoplasms
8
Breast Neoplasms
5
Neoplasms
4
Head and Neck Neoplasms
3
Central Nervous System Neoplasms
3
Uterine Cervical Neoplasms
2
Unspecified Adult Solid Tumor, Protocol Specific
2
Squamous Cell Carcinoma of Head and Neck
2
Prostatic Neoplasms
2
Oligodendroglioma
2
Melanoma
2
Lung Neoplasms
2
Glioma
2
Glioblastoma
2
Ependymoma
2
Carcinoma, Non-Small-Cell Lung
2
Astrocytoma
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Sarcoma, Ewing
1
Sarcoma
1
Salivary Gland Neoplasms
1
Rectal Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neoplasm Metastasis
1
Metastatic Castration-resistant Prostate Cancer
1
Lymphoma
1
Leukemia, Myeloid, Acute
1
Interventions
Radiotherapy
7
Brachytherapy
6
Surveys and Questionnaires
4
Magnetic Resonance Spectroscopy
4
durvalumab
3
Radiosurgery
3
Methods
3
tremelimumab
2
aldesleukin
2
Topotecan
2
Radiation
2
Palliative Care
2
Paclitaxel
2
Immunoglobulin G
2
Gemcitabine
2
Early Intervention, Educational
2
Disulfides
2
Dehydroepiandrosterone
2
Counseling
2
Capecitabine
2
Bevacizumab
2
Behavior Therapy
2
Adoptive Transfer
2
zimberelimab
1
temsirolimus
1
talazoparib
1
rocakinogene sifuplasmid
1
liposomal doxorubicin
1
fludarabine phosphate
1
dostarlimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Vaginal Neoplasms
×
alovudine
×
Clear all
NCT01399658
2023-03-14
AMIGO
Dana-Farber Cancer Institute
Phase 2
Completed
93 enrolled
5 charts